Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 21 Sep 2021
Views: 1086
Dr Danny Nguyen - City of Hope, Orange County, USA

Dr Danny Nguyen speaks to ecancer about managing patients with EGFR exon 20 insertion mutated NSCLC, and EGFR TKI toxicity.

Dr Nguyen discusses the comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors.

He also mentions other emerging data from recent conferences regarding the treatment of EGFR exon 20 ins mutation NSCLC patients.

He also looks at the data on managing EGFR TKI toxicity from ESMO and WCLC 2021, including toxicity profiles of mobocertinib, DZD9008, and amivantamab.

He concludes by talking about what the future looks like for the treatment of EGFR exon 20 ins NSCLC.

This programme has been supported by an unrestricted educational grant from Takeda.